Vanita R Aroda

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 60

Top Topics

Glycemic Control

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

BMJ open diabetes research & care

This page only lists publications with an associated author ORCID identifier.

Publications

Jonah A Hoyt, Emily Cozzi, David A D'Alessio, Chris C Thompson, Vanita R Aroda
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes. Diabetes, obesity & metabolism (2024)
Setor Kwadzo Kunutsor, Victoria G Balasubramanian, Francesco Zaccardi, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Setor Kwadzo Kunutsor, Victoria G Balasubramanian, Francesco Zaccardi, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes, obesity & metabolism (2024)
Setor Kwadzo Kunutsor, Francesco Zaccardi, Victoria G Balasubramanian, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Melanie Jane Davies, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes, obesity & metabolism (2024)
Setor Kwadzo Kunutsor, Francesco Zaccardi, Victoria G Balasubramanian, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Melanie Jane Davies, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes, obesity & metabolism 26 (5) (2024)
Vanita R Aroda, Nick Nielsen, Kamal K Mangla, Jasjit Multani, Victoria Divino, Tarlan Namvar, Jigar Rajpura
Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis. BMJ open diabetes research & care 12 (2) (2024)
Kamlesh Khunti F MedSci, Francesco Zaccardi, Aslam Amod, Vanita R Aroda, Pablo Aschner, Stephen Colagiuri, Viswanathan Mohan, Juliana Chung Ngor Chan
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia (2024)
Setor Kwadzo Kunutsor, Victoria G Balasubramanian, Francesco Zaccardi, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Manasi Tannu, Lisa Kaltenbach, Neha J Pagidipati, Darren K McGuire, Vanita R Aroda, Pradipta R Ray, Nitin Kondamudi, Hussein R Al-Khalidi, Renato Deláscio Lopes, Matthew A Cavender, Adam James Nelson, Julienne Kirk, Ildiko Lingvay, Melissa Magwire, Caroline Regina Richardson, Laura E Webb, Monica Leyva, Ambarish Pandey, Alana Washington, Jonathan Pak, Tanya Gaynor, Waqar Khan, Patrick Weston, Christopher B Granger, Jennifer B Green
Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial. Circulation (2024)
Vanita R Aroda, Nick Nielsen, Kamal K Mangla, Jasjit Multani, Victoria Divino, Tarlan Namvar, Jigar Rajpura
Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis. BMJ open diabetes research & care 12 (2) (2024)
Jonah A Hoyt, Emily Cozzi, David A D'Alessio, Chris C Thompson, Vanita R Aroda
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Vanita R Aroda, Nick Nielsen, Kamal K Mangla, Jasjit Multani, Victoria Divino, Tarlan Namvar, Jigar Rajpura
Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis. BMJ open diabetes research & care 12 (2) (2024)
Jonah A Hoyt, Emily Cozzi, David A D'Alessio, Chris C Thompson, Vanita R Aroda
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes. Diabetes, obesity & metabolism 26 (6) (2024)
Setor Kwadzo Kunutsor, Francesco Zaccardi, Victoria G Balasubramanian, Clare L Gillies, Vanita R Aroda, Samuel Seidu, Melanie Jane Davies, Kamlesh Khunti F MedSci
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes, obesity & metabolism 26 (5) (2024)
Vanita R Aroda, Nick Nielsen, Kamal K Mangla, Jasjit Multani, Victoria Divino, Tarlan Namvar, Jigar Rajpura
Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis. BMJ open diabetes research & care 12 (2) (2024)
Vanita R Aroda, Juan Pablo Frias, Li-Nong Ji, Elisabeth Niemoeller, My-Liên Nguyên-Pascal, Karl Denkel, Melanie Espinasse, Hailing Guo, SeungJae Baek, JaeDuk Choi, Ildiko Lingvay
Efficacy and Safety of Once-Weekly Efpeglenatide in People with Suboptimally Controlled Type 2 Diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S Randomised Controlled Trials. Diabetes, obesity & metabolism (2023)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard E Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, Sonia Y Angell, Vanita R Aroda, Alice Y Y Cheng, Thomas P A Danne, Justin Basile Echouffo-Tcheugui, Stephanie L Fitzpatrick, Meghana D Gadgil, Francesco Rubino, Anna L Gloyn, Jennifer B Green, Ania M Jastreboff, Alka M Kanaya, Namratha R Kandula, Csaba P Kovesdy, Neda Laiteerapong, Kristen J Nadeau, Jeremy H Pettus, Pradipta R Ray, Jennifer E Posey, Camille E Powe, Casey M Rebholz, Michael R Rickels, Naveed Sattar, Jonathan Edward Shaw, Emily K Sims, Kristina M Utzschneider, Adrian Vella, Cuilin Zhang
Reflecting on a Year at the Helm of Diabetes Care. Diabetes care 47 (1) (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, Sonia Y Angell, Vanita R Aroda, Alice Y Y Cheng, Thomas P A Danne, Justin Basile Echouffo-Tcheugui, Stephanie L Fitzpatrick, Meghana D Gadgil, Francesco Rubino, Anna L Gloyn, Jennifer B Green, Ania M Jastreboff, Alka M Kanaya, Namratha R Kandula, Csaba P Kovesdy, Neda Laiteerapong, Kristen J Nadeau, Jeremy H Pettus, Pradipta R Ray, Jennifer E Posey, Camille E Powe, Casey M Rebholz, Michael R Rickels, Naveed Sattar, Jonathan Edward Shaw, Emily K Sims, Kristina M Utzschneider, Adrian Vella, Cuilin Zhang
Reflecting on a Year at the Helm of Diabetes Care. Diabetes care 47 (1) (2023)
Vanita R Aroda, Umut Erhan, Peter Jelnes, Juris J Meier, Morten Tind Abildlund, Richard Pratley, Tina Vilsbøll, Mansoor Husain
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes, obesity & metabolism (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Ronald M Goldenberg, Vanita R Aroda, Liana K Billings, Anders Meller Donatsky, Marie Frederiksen, David C Klonoff, Balamurali Kalyanam, Richard M Bergenstal
Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Barbara I Gulanski, Nicole M Butera, Heidi Krause-Steinrauf, Judith H Lichtman, Tasma Harindhanavudhi, Jennifer B Green, Colleen E Suratt, Hiba AbouAssi, Cyrus V Desouza, Andrew J Ahmann, Deborah J Wexler, Vanita R Aroda, null null
Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort. BMJ open diabetes research & care 11 (2) (2023)
Vanita R Aroda, Lawrence Blonde, Richard E Pratley
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in endocrine & metabolic disorders 23 (5) (2022)
Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care 45 (11) (2022)
Melanie Jane Davies, Vanita R Aroda, Billy S Collins, Robert A Gabbay, Jennifer Green, Nisa M Maruthur, Sylvia E Rosas, Stephano Del Prato, Chantal Mathieu, Geltrude Mingrone, Ellen Burgess, Tsvetalina Tankova, Apostolos Tsapas, John B Buse
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65 (12) (2022)
Vanita R Aroda, Robert Bauer, Erik Christiansen, Martin Haluzík, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock, Juris J Meier
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes, obesity & metabolism 24 (7) (2022)
Kamlesh Khunti F MedSci, Vanita R Aroda
Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. Diabetes care 45 (4) (2022)
Kamlesh Khunti F MedSci, Vanita R Aroda, Deepak L Bhatt, Biykem Bozkurt, John B Buse, Hiddo J Lambers Heerspink, Catherine M Viscoli, Carolyn Su Ping Lam, Nikolaus Marx, John Joseph Valentine McMurray, Scott D Solomon, Mikhail Naum Kosiborod
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. Diabetes, obesity & metabolism 24 (11) (2022)
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, Sonia Y Angell, Vanita R Aroda, Jessica R Castle, Alice Y Y Cheng, Thomas P A Danne, Justin Basile Echouffo-Tcheugui, Jose C Florez, Meghana D Gadgil, Francesco Rubino, Jennifer B Green, Ania M Jastreboff, Alka M Kanaya, Namratha R Kandula, Csaba P Kovesdy, Neda Laiteerapong, Kristen J Nadeau, Pradipta R Ray, Camille E Powe, Casey M Rebholz, Michael R Rickels, Naveed Sattar, Jonathan Edward Shaw, Emily K Sims, Kristina M Utzschneider, Adrian Vella, Cuilin Zhang
"The Times They Are A-Changin'" at Diabetes Care. Diabetes care 46 (1) (2022)
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, Sonia Y Angell, Vanita R Aroda, Jessica R Castle, Alice Y Y Cheng, Thomas P A Danne, Justin Basile Echouffo-Tcheugui, Jose C Florez, Meghana D Gadgil, Francesco Rubino, Jennifer B Green, Ania M Jastreboff, Alka M Kanaya, Namratha R Kandula, Csaba P Kovesdy, Neda Laiteerapong, Kristen J Nadeau, Pradipta R Ray, Camille E Powe, Casey M Rebholz, Michael R Rickels, Naveed Sattar, Jonathan Edward Shaw, Emily K Sims, Kristina M Utzschneider, Adrian Vella, Cuilin Zhang
"The Times They Are A-Changin'" at Diabetes Care. Diabetes care 46 (1) (2022)
Steven E Kahn, Cheryl A M Anderson, John B Buse, Elizabeth Selvin, Sonia Y Angell, Vanita R Aroda, Jessica R Castle, Alice Y Y Cheng, Thomas P A Danne, Justin Basile Echouffo-Tcheugui, Jose C Florez, Meghana D Gadgil, Francesco Rubino, Jennifer B Green, Ania M Jastreboff, Alka M Kanaya, Namratha R Kandula, Csaba P Kovesdy, Neda Laiteerapong, Kristen J Nadeau, Pradipta R Ray, Camille E Powe, Casey M Rebholz, Michael R Rickels, Naveed Sattar, Jonathan Edward Shaw, Emily K Sims, Kristina M Utzschneider, Adrian Vella, Cuilin Zhang
"The Times They Are A-Changin'" at Diabetes Care. Diabetes care 46 (1) (2022)
Vanita R Aroda, Robert H Eckel
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. Diabetes, obesity & metabolism 24 (12) (2022)
Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Pablo Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stephano Del Prato
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes, obesity & metabolism 23 (6) (2021)
Ana Maria Stanton, Muthiah Vaduganathan, Lee-Shing Chang, Alexander Turchin, James L Januzzi, Vanita R Aroda
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. Current diabetes reports 21 (10) (2021)
Geremia B Bolli, Alice Cheng, Bernard Charbonnel, Vanita R Aroda, Jukka Westerbacka, Zsolt Bosnyak, Emmanuelle Boëlle-Le Corfec, Julio Rosenstock
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial. Diabetes, obesity & metabolism 23 (7) (2021)
Ronald M Goldenberg, Vanita R Aroda, Liana K Billings, A Sia Louise Christiansen, Anders Meller Donatsky, Ehsan Parvaresh Rizi, Gracjan Podgorski, Katarina Raslova, David C Klonoff, Richard M Bergenstal
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes, obesity & metabolism 23 (11) (2021)
Vanita R Aroda, Mads Faurby, Søren Lophaven, Josh Noone, Michael Lyng Wolden, Ildiko Lingvay
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes, obesity & metabolism 23 (9) (2021)
Lawrence Blonde, Julio Rosenstock, Juan Pablo Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stephano Del Prato, Vanita R Aroda
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes care 44 (3) (2021)
Richard E Pratley, Vanita R Aroda, Andrei-Mircea Catarig, Ildiko Lingvay, Jörg Lüdemann, Emre Yildirim, Adie Viljoen
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ open 10 (11) (2020)
Nicola Morea, Chang Ye, Josep Vidal, Vanita R Aroda, Minzhi Liu, Aramesh Saremi, Francesco Giorgino
iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study. Diabetes, obesity & metabolism 22 (9) (2020)
Giorgio Sesti, Lars Bardtrum, Selcuk Dagdelen, Natalie Halladin, Martin Haluzík, Petra Őrsy, Martin Rodríguez, Vanita R Aroda
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice. Diabetes, obesity & metabolism 22 (5) (2020)
Stephano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes, obesity & metabolism 22 (9) (2020)
William I Sivitz, Lawrence S Phillips, Deborah J Wexler, Stephen P Fortmann, Anne W Camp, Margaret Tiktin, Magalys Perez, Jacqueline Craig, Priscilla A Hollander, Andrea Cherrington, Vanita R Aroda, Meng Hee Tan, Jonathan Krakoff, Neda Rasouli, Nicole M Butera, Naji Younes, null null
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes care 43 (5) (2020)
Eugene E Wright, Vanita R Aroda
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate medicine 132 (sup2) (2020)
Christopher K Rayner, Chinmay S Marathe, Vanita R Aroda, Craig Whittington, Steve Kanters, Patricia Guyot, Alka Shaunik, Michael Horowitz
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. Diabetes, obesity & metabolism 23 (1) (2020)
Philip D Home, Vanita R Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra, Mir-Masoud Pourrahmat
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison. Diabetes, obesity & metabolism 22 (11) (2020)
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík, null null
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes care 42 (9) (2019)
Deborah J Wexler, Heidi Krause-Steinrauf, Jill P Crandall, Hermes J Florez, Sophia H Hox, Alexander Kuhn, Ajay Sood, Chantal Underkofler, Vanita R Aroda, null null
Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes care 42 (11) (2019)
Vanita R Aroda, Matthew S Capehorn, Louis Chaykin, Juan Pablo Frias, Nanna L Lausvig, Stanislava Macura, Jörg Lüdemann, Sten Madsbad, Julio Rosenstock, Omur Tabak, Sayeh Tadayon, Stephen C Bain
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism 22 (3) (2019)
Bernard Zinman, Vanita R Aroda, John B Buse, Bertrand Cariou, Stewart B Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki, null null
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes care 42 (12) (2019)
Vanita R Aroda, Trine Saugstrup, John B Buse, Morten Donsmark, Jeppe Zacho, Melanie Jane Davies
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, obesity & metabolism 21 (10) (2019)
Lawrence Blonde, Julio Rosenstock, Stephano Del Prato, Robert R Henry, Naim Shehadeh, Juan Pablo Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes care 42 (11) (2019)
Vanita R Aroda
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes, obesity & metabolism (2018)
Erin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, Myrlene A Staten, Patricia R Sheehan, Michael R Lewis, Anne Peters, Sun H Kim, Ranee Chatterjee, Vanita R Aroda, Chhavi Chadha, Lisa M Neff, Irwin G Brodsky, Clifford Rosen, Cyrus V Desouza, John P Foreyt, Daniel S Hsia, Karen C Johnson, Philip Raskin, Sangeeta R Kashyap, Patrick O'Neil, Lawrence S Phillips, Neda Rasouli, Emilia P Liao, David C Robbins, Anastassios G Pittas, null null
Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes care 41 (8) (2018)